TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04347187
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral anticoagulants, dual or triple antithrombotic theraphy
Study: NCT04157985
Drug: Continue PD-1/PD-L1 Inhibitors treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued treatment with PD-1/PD-L1-1 inhibitor
Study: NCT03785964
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic nirogacestat 50 mg tablet
Study: NCT03744182
Drug: Placebo of HM15211
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile, matching solution in pre-filled syringes
Study: NCT03029429
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral theophylline
Study: NCT03029429
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo
Study: NCT01992289
Drug: EDI200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
Study: NCT00996866
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
Study: NCT00671879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet
Study: NCT03448042
Drug: Runimotamab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runimotamab will be administered via IV infusion until disease progression, intolerable toxicity, or any other discontinuation criteria are met.
Study: NCT04545762
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenously (IV)
Study: NCT01001897
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
Study: NCT00287027
Drug: Risperdal Long Acting Injectable Antipsychotic Medication
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02562768
Drug: LY3154207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02562768
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03397173
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid will be administered orally daily at 1 g/day three days prior to start azacitidine and then continues daily for a total of 28 days of each 28 day cycle. No dose modifications will be permitted during the treatment period.
Study: NCT01336192
Drug: Best supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care
Study: NCT00485433
Drug: SKY0402
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKY0402 given during hernia repair
Study: NCT02755298
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03664232
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a matching placebo orally twice daily for 12 weeks.
Study: NCT00003520
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT00909727
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet given orally q12h for up to 48 weeks
Study: NCT02110420
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once daily for up to 14 days depending on the Part of the study
Study: NCT03788681
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01339910
Drug: Busulfan and Cyclophosphamide
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Bu/Cy)~* Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m\^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m\^2, respectively) on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Study: NCT01339910
Drug: Cyclophosphamide and Total Body Irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: (Cy/TBI)~* TBI: 1200-1420 cGy on Days -7 to -4~* Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)
Study: NCT03622502
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 2.0 ng/ml)
Study: NCT03622502
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline was infused over 10 min before end of the surgery
Study: NCT02322879
Drug: First Treatment Period
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: (duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
Study: NCT02322879
Drug: Second Treatment Period
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: (duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
Study: NCT03778996
Drug: Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral combination therapy for cancer
Study: NCT00118300
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Study: NCT02386059
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: received normal saline, intravenously
Study: NCT03400995
Drug: AK0529
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution containing 300 mg radiolabelled AK0529.
Study: NCT03896685
Drug: Control arm MDR-TB regimen, designed according to latest WHO guidelines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control arm MDR-TB regimen, designed according to latest WHO guidelines (might include bedaquiline, delamanid, linezolid, clofazimine, or all of these drugs).
Study: NCT00866788
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received a single subcutaneous placebo injection on Day 0 of the study.
Study: NCT04081337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT04485988
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of medication
Study: NCT02491788
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00974493
Drug: Antibiotics
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.~Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines.
Study: NCT03238742
Drug: Xuebijing Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml Xuebijing Injection every 12 hours for 5 days
Study: NCT03238742
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200ml normal saline every 12 hours for 5 days
Study: NCT03046992
Drug: YH25448
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dose Escalation: YH25448 20mg\~320mg, PO~* Dose Expansion: YH25448 40mg\~240mg, PO~* Dose Extension: Recommended Dose 240mg of YH25448
Study: NCT00772577
Drug: Aliskiren Hydrochlorothiazide
Normalized name: aliskiren / hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
Study: NCT01891513
Drug: ACE inhibitor + exercise
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
Study: NCT01891513
Drug: Thiazide diuretic + exercise
Normalized name: althiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
Study: NCT03080987
Drug: JNJ-64179375 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
Study: NCT03080987
Drug: JNJ-64179375 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
Study: NCT03080987
Drug: JNJ-64179375 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
Study: NCT02688400
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02688400
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00389506
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02424305
Drug: LEO 43204 gel 0.018%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02424305
Drug: LEO 43204 gel 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02424305
Drug: LEO 43204 gel 0.037%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151981
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomization to either Osimertinib or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (Osimertinib:platinum-based doublet-chemotherapy) ratio
Study: NCT04106219
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV.
Study: NCT00195273
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
Study: NCT02186873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo.
Study: NCT04875962
Drug: UCB0599
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period.
Study: NCT04875962
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding.
Study: NCT01484041
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
Study: NCT02372370
Drug: MAL Control.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
Study: NCT00867685
Drug: AZD2624
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg AZD2624 liquid suspension, PO
Study: NCT00867685
Drug: AZD2624
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
Study: NCT00161473
Drug: placebo (inert substance)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
Study: NCT04342273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered once daily at Day 1 through Day 7
Study: NCT01635985
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
Study: NCT01635985
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
Study: NCT01635985
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
Study: NCT01635985
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
Study: NCT01635985
Drug: AZD5423
Approvals — FDA: no, EMA: no, PMDA: no
Description: dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
Study: NCT00752323
Drug: aminolevulinic acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01894984
Drug: Oral atypical anti-psychotic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
Study: NCT03835819
Drug: IMGN853
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirvetuximab soravtansine is an antibody-drug conjugate.
Study: NCT02572583
Drug: Liugan Shuangjie Heji
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00877110
Drug: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight\<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
Study: NCT00598702
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
Study: NCT02413372
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00258284
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
Study: NCT03024814
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The first group will receive acetaminophen as the following~1. Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.~2. Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.
Study: NCT03024814
Drug: Dextrose 5
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: The second group will receive placebo (D5W) as the following~1. Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.~2. Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days.
Study: NCT01331733
Drug: hMG-HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02101788
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02733237
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo (40 IU)
Study: NCT02497612
Drug: Ferroquine SSR97193
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Capsules Route of administration: oral
Study: NCT00611533
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
Study: NCT00799006
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be given placebo or PF-04620110
Study: NCT01865188
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental monotherapy doses
Study: NCT01865188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator dose
Study: NCT01200524
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet
Study: NCT01200524
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tablet
Study: NCT01200524
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01978418
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given once as a dose of four puffs at 30-60 minutes of age
Study: NCT00997880
Drug: Rosuvastatin calcium 40mg
Normalized name: Rosuvastatin Calcium 40mg Oral tablet
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin calcium 40mg
Study: NCT01214603
Drug: LY2090314
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04115449
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline as a placebo will be infused over a period of ten minutes
Study: NCT00997880
Drug: Rosuvastatin calcium10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10mg
Study: NCT01359007
Drug: Irinotecan, Oxaliplatin, Leucovorin, 5-FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
Study: NCT00384033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets and capsules, once daily dosing for 8 weeks
Study: NCT01134731
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-5 placebo capsules
Study: NCT01298310
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection
Study: NCT00689078
Drug: Prednisolone Acetate 1%
Normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study: NCT00689078
Drug: Prednisolone Acetate 0.12%
Normalized name: PREDNISOLONE ACETATE 0.12% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study: NCT02010723
Drug: sclerotherapy with aethoxysclerol foam
Approvals — FDA: no, EMA: no, PMDA: no
Description: foam sclerotherapy with aethoxysclerol foam
Study: NCT00689078
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop in both eyes (OU) BID starting at Visit 2 (Day 0) for 6 days. Then in each eye QID starting the day after Visit 5 (Day 21) for 6 days.
Study: NCT01856907
Drug: Placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will evaluate effect of lifestyle and diet only
Study: NCT00260325
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03292575
Drug: Anticoagulants
Normalized name: ANTICOAGULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00735683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: includes diet, physical activity, and lifestyle modification
Study: NCT02033525
Drug: XCEL-M-ALPHA and standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
Study: NCT02595138
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01944033
Drug: Bricanyl/Iprovent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Terbutaline sulfate (2ml) + 0,5 mg Ipratropium bromide (2ml) + 1ml serum saline in each nebulization which is repeated three times during 1 hour and every 4 hours during the first 24 hour protocol
Study: NCT00735241
Drug: FOLFOX6 cycles 1-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
Study: NCT00735241
Drug: FOLFOX6 cycles 4 onwards
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
Study: NCT01561378
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 microliters of normal saline will be administered per nostril using an intranasal mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
Study: NCT01460368
Drug: LY2409021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally